Avantor (AVTR)
NYSE:AVTR
Want to see AVTR full AI Analyst Report?
Top Page
Avantor
(NYSE:AVTR)
Select Model
Select Model
Rating:54Neutral
Price Target:
$8.00
▼(-6.10% Downside)
Action:Reiterated
Date:05/13/26
The score is held back primarily by weakened profitability and sharp TTM revenue contraction, alongside a technically weak price trend. Offsetting these are resilient cash flow, improved leverage, and an earnings-call outlook that reaffirms guidance and points to stabilization with a potential H2 organic-growth recovery—though near-term demand and margin headwinds keep risk elevated.
Positive Factors
Cash generation
Avantor’s operating cash flow and positive free cash flow despite accounting losses show durable internal funding capacity. Sustained FCF (~$439M TTM) supports debt paydown, targeted capex and the Revival program, giving the company flexibility to invest in growth and structural improvements over coming quarters.
Negative Factors
Revenue and profit deterioration
Sharp TTM revenue decline and a swing to sizable net losses indicate structural scale erosion. Losing scale pressures fixed-cost absorption and ROE, and restoring prior profitability requires meaningful, sustained revenue recovery to reverse margin deleverage and rebuild investor returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation
Avantor’s operating cash flow and positive free cash flow despite accounting losses show durable internal funding capacity. Sustained FCF (~$439M TTM) supports debt paydown, targeted capex and the Revival program, giving the company flexibility to invest in growth and structural improvements over coming quarters.
Read all positive factors
Avantor Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much each business segment contributes to total revenue, indicating the company’s diversification and which segments are leading growth or facing headwinds.
Shows how much each business segment contributes to total revenue, indicating the company’s diversification and which segments are leading growth or facing headwinds.
Data provided by:
The Fly
The FlyAvantor (AVTR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.19B
Dividend YieldN/A
Average Volume (3M)9.53M
Price to Earnings (P/E)30.7
Beta (1Y)0.88
Revenue Growth-1.99%
EPS Growth-176.82%
CountryUS
Employees13,500
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.80
Shares Outstanding682,755,430
10 Day Avg. Volume9,338,826
30 Day Avg. Volume9,531,878
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.40
Price to Sales (P/S)1.19
P/FCF Ratio15.70
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue0.76
Enterprise Value/Gross Profit2.36
Enterprise Value/Ebitda37.94
Forecast
1Y Price Target
$8.29Price Target Upside-2.75% Downside
Rating ConsensusHold
Number of Analyst Covering8
EPS Forecast (FY)0.79
Revenue Forecast (FY)$6.50B
Avantor Business Overview & Revenue Model
Company Description
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers ma...
How the Company Makes Money
Avantor primarily makes money by selling products and services used throughout the life-sciences and advanced-technology workflows, generating revenue when customers purchase consumables, materials, and related services on a recurring basis. Key r...
Avantor Earnings Call Summary
Earnings Call Date:Apr 29, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 23, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: clear operational progress from the Revival program (leadership refresh, digital and kaizen-driven efficiency projects, improved BMP order trends and e-commerce gains) and a Q1 outperformance on EPS versus expectations. However, meaningful near-term revenue declines, margin pressure from mix and freight, customer prebates depressing early cash flow, geopolitical inflationary risk ($10–$20M headwind) and a CFO transition temper the outlook. Management reaffirmed guidance and expects stabilization in H1 with a path to organic growth in H2, but execution and macro risks will determine whether that recovery materializes.Positive Updates
Company-wide Q1 results and profitability
Q1 revenue of $1.581 billion (flat reported, down 4% organic). Adjusted EBITDA of $219 million (13.9% margin). Adjusted EPS of $0.17, ahead of expectations.
Negative Updates
Ongoing organic revenue declines
Enterprise organic revenue declined 4% in Q1. VWR down 5% organically and BMP down 2% organically. Management expects enterprise organic growth to be roughly -5% in Q2 and BMP to worsen by more than 500 basis points year-over-year in Q2 versus Q1.
Read all updates
Q1-2026 Updates
Positive
Negative
Company-wide Q1 results and profitability
Q1 revenue of $1.581 billion (flat reported, down 4% organic). Adjusted EBITDA of $219 million (13.9% margin). Adjusted EPS of $0.17, ahead of expectations.
Read all positive updates
Company Guidance
Avantor reaffirmed 2026 guidance and gave Q2 adjusted EPS guidance of $0.19–$0.20 while flagging an incremental $10–$20 million operating‑income headwind from Middle East–related inflation; management said VWR’s growth rate hit a trough in Q1 and should improve to positive organic growth in H2, BMP’s growth rate should trough in Q2 (Q2 organic growth to be >500 bps worse than Q1), and adjusted operating margins for both segments are expected to increase sequentially Q1→Q2; Q1 results used as context included $1.581 billion revenue (organic -4%), adjusted EBITDA $219 million (13.9% margin), adjusted EPS $0.17, free cash flow $25 million ($39 million excl. restructuring), ~$105 million of debt repaid, and adjusted net leverage of 3.3x with debt reduction the top capital priority and a commitment to get sustainably below 3x; segment detail: VWR Q1 revenue $1.15 billion (organic -5%), adjusted operating income $105 million (9.2% margin), and BMP Q1 revenue $431 million (organic -2%), adjusted operating income $103 million (23.8% margin) with BMP book‑to‑bill >1.1x; additional operational metrics noted: ~2% YTD headcount reduction, 12 CapEx projects sanctioned and $20 million of previously announced incremental investment.Avantor Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
58
Neutral
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.55B | 6.55B | 6.78B | 6.97B | 7.51B | 7.39B |
| Gross Profit | 2.11B | 2.14B | 2.28B | 2.36B | 2.60B | 2.50B |
| EBITDA | 131.10M | 138.70M | 1.48B | 1.10B | 1.52B | 1.35B |
| Net Income | -551.40M | -530.20M | 711.50M | 321.10M | 686.50M | 572.60M |
Balance Sheet | ||||||
| Total Assets | 11.66B | 11.79B | 12.11B | 12.97B | 13.46B | 13.90B |
| Cash, Cash Equivalents and Short-Term Investments | 279.30M | 365.40M | 261.90M | 262.90M | 372.90M | 301.70M |
| Total Debt | 37.00M | 3.95B | 4.06B | 5.54B | 6.29B | 7.02B |
| Total Liabilities | 6.07B | 6.23B | 6.16B | 7.72B | 8.61B | 9.70B |
| Stockholders Equity | 5.59B | 5.57B | 5.96B | 5.25B | 4.86B | 4.20B |
Cash Flow | ||||||
| Free Cash Flow | 438.90M | 495.00M | 692.00M | 723.60M | 710.20M | 842.50M |
| Operating Cash Flow | 573.20M | 623.80M | 840.80M | 870.00M | 843.60M | 953.60M |
| Investing Cash Flow | -134.30M | -130.50M | 438.90M | -143.70M | -109.60M | -4.12B |
| Financing Cash Flow | -483.00M | -409.40M | -1.28B | -843.70M | -648.70M | 3.22B |
Avantor Technical Analysis
Negative
8.52
Price Trends
7.95
Negative
9.31
Negative
10.89
Negative
Market Momentum
-0.11
Positive
40.58
Neutral
5.63
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVTR, the sentiment is Negative. The current price of 8.52 is above the 20-day moving average (MA) of 7.98, above the 50-day MA of 7.95, and below the 200-day MA of 10.89, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 40.58 is Neutral, neither overbought nor oversold. The STOCH value of 5.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AVTR.
Avantor Risk Analysis
Avantor disclosed 39 risk factors in its most recent earnings report. Avantor reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Avantor Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $20.73B | 16.58 | -2.35% | 1.10% | 7.87% | 69.44% | |
66 Neutral | $2.37B | 27.35 | 0.31% | 1.37% | 6.25% | -94.37% | |
66 Neutral | $22.72B | 26.50 | 10.92% | ― | 1.79% | ― | |
65 Neutral | $8.11B | 20.33 | 6.77% | 5.33% | -7.41% | -56.10% | |
54 Neutral | $5.19B | 30.69 | -9.59% | ― | -1.99% | -176.82% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $11.72B | -22.61 | -17.68% | 2.88% | -8.63% | -524.43% |
* Healthcare Sector Average
AVTR
Avantor
7.64
-5.83
-43.28%
ALB
Albemarle
169.00
110.70
189.90%
EMN
Eastman Chemical
68.15
-10.34
-13.18%
KWR
Quaker Chemical
134.02
28.37
26.85%
SQM
Sociedad Quimica Y Minera SA
80.45
46.47
136.76%
WLK
Westlake Corporation
88.66
13.98
18.72%
Avantor Corporate Events
Executive/Board ChangesShareholder Meetings
Avantor Shareholders Approve Proposals at 2026 Annual Meeting
Positive
May 12, 2026
Avantor, Inc. held its 2026 Annual Meeting of Stockholders on May 7, 2026, where shareholders elected nine directors to one-year terms ending at the 2027 annual meeting and approved, on an advisory basis, the 2025 compensation of the company’...
Business Operations and StrategyExecutive/Board Changes
Avantor Appoints New Executive VP and Transformation Leader
Positive
Apr 23, 2026
On April 17, 2026, Avantor, Inc. announced that Executive Vice President of Bioscience and Medtech Products, Benoit Gourdier, would transition into a new role supporting segment integration activities before leaving the company by December 31, 202...
Executive/Board Changes
Avantor Announces CFO Resignation and Interim Finance Leadership
Neutral
Apr 1, 2026
Avantor announced that on March 26, 2026, Executive Vice President and Chief Financial Officer R. Brent Jones notified the company of his decision to resign to join a business outside the life sciences sector, triggering a transition period under ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.